Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cyclin-dependent kinase 4 | Starlite/ChEMBL | No references |
Homo sapiens | cyclin-dependent kinase 3 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | mitogen-activated protein kinase 5 | cyclin-dependent kinase 3 | 305 aa | 303 aa | 32.0 % |
Trypanosoma brucei | mitogen-activated protein kinase 5 | cyclin-dependent kinase 4 | 303 aa | 312 aa | 29.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | CMGC family protein kinase | 0.0053 | 0 | 0.5 |
Loa Loa (eye worm) | CMGC/CDK/CDC2 protein kinase | 0.0053 | 0 | 0.5 |
Echinococcus granulosus | cyclin dependent kinase 5 | 0.0053 | 0 | 0.5 |
Mycobacterium tuberculosis | Isocitrate lyase Icl (isocitrase) (isocitratase) | 0.1019 | 1 | 0.5 |
Toxoplasma gondii | cell-cycle-associated protein kinase CDK, putative | 0.0053 | 0 | 0.5 |
Plasmodium vivax | protein kinase Crk2 | 0.0053 | 0 | 0.5 |
Trypanosoma cruzi | cdc2-related kinase 1 | 0.0053 | 0 | 0.5 |
Leishmania major | cell division protein kinase 2,cdc2-related kinase | 0.0053 | 0 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0053 | 0 | 0.5 |
Trypanosoma brucei | cdc2-related kinase 1 | 0.0053 | 0 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0053 | 0 | 0.5 |
Trypanosoma brucei | cdc2-related kinase 3 | 0.0053 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable isocitrate lyase AceAb [second part] (isocitrase) (isocitratase) (Icl) | 0.1019 | 1 | 0.5 |
Plasmodium falciparum | protein kinase 5 | 0.0053 | 0 | 0.5 |
Mycobacterium ulcerans | isocitrate lyase Icl | 0.1019 | 1 | 0.5 |
Loa Loa (eye worm) | CMGC/CDK/CDC2 protein kinase | 0.0053 | 0 | 0.5 |
Mycobacterium ulcerans | isocitrate lyase AceAb | 0.1019 | 1 | 0.5 |
Echinococcus granulosus | cyclin dependent kinase 1 | 0.0053 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable isocitrate lyase AceAa [first part] (isocitrase) (isocitratase) (Icl) | 0.1019 | 1 | 0.5 |
Brugia malayi | cell division control protein 2 homolog | 0.0053 | 0 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0053 | 0 | 0.5 |
Entamoeba histolytica | cell division protein kinase 2, putative | 0.0053 | 0 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0053 | 0 | 0.5 |
Echinococcus multilocularis | cyclin dependent kinase 1 | 0.0053 | 0 | 0.5 |
Echinococcus granulosus | 5'partial|cyclin dependent kinase 1 | 0.0053 | 0 | 0.5 |
Trypanosoma cruzi | cdc2-related kinase 3 | 0.0053 | 0 | 0.5 |
Trypanosoma cruzi | cdc2-related kinase 3 | 0.0053 | 0 | 0.5 |
Giardia lamblia | Kinase, CMGC CDK | 0.0053 | 0 | 0.5 |
Entamoeba histolytica | cell division protein kinase 2, putative | 0.0053 | 0 | 0.5 |
Brugia malayi | Protein kinase domain containing protein | 0.0053 | 0 | 0.5 |
Echinococcus granulosus | cyclin dependent kinase | 0.0053 | 0 | 0.5 |
Loa Loa (eye worm) | CMGC/CDK/CDK5 protein kinase | 0.0053 | 0 | 0.5 |
Leishmania major | cell division related protein kinase 2,cdc2-related kinase | 0.0053 | 0 | 0.5 |
Trypanosoma cruzi | cdc2-related kinase 1 | 0.0053 | 0 | 0.5 |
Echinococcus multilocularis | cyclin dependent kinase 1 | 0.0053 | 0 | 0.5 |
Echinococcus multilocularis | cyclin dependent kinase 5 | 0.0053 | 0 | 0.5 |
Giardia lamblia | Kinase, CMGC CDK | 0.0053 | 0 | 0.5 |
Echinococcus multilocularis | cyclin dependent kinase | 0.0053 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 7 nM | BindingDB_Patents: Biological Assay. An assay for monitoring CDK4/cyclin D1-catalyzed phosphorylation of pRb at the Ser780 site was performed using TR-FRET in a 384-well format, and was used for IC50 determination and kinetic analysis. The reaction was carried out in a 30 uL volume containing 0.3 nM CDK4/cyclin D1, 150 nM biotin-pRb (773-924), 3 uM ATP, and 1.3% DMSO (or compound in DMSO) in the assay buffer (50 mM HEPES-Na, pH 7.5; 5 mM MgCl2, 1 mM DTT, 0.02% Tween-20, and 0.05% BSA). 3 uM ATP was added last to initiate the reaction. The reaction was quenched with 10 uL of 240 mM EDTA-Na (pH 8.0) after 60 min incubation at 22 C. The signal was developed by the addition of 40 uL detection solution containing 40 nM SA-APC, 143 ng/mL anti-phospho-pRb (S780) antibody, and 1 nM Eu-W1024 anti-rabbit IgG antibody in the detection buffer (50 mM HEPES-Na, pH 7.5, 60 mM EDTA-Na, pH 8.0, 0.05% BSA, and 0.1% Triton X-100). After 60 min incubation in the dark, the plate was read on Envision. | ChEMBL. | No reference |
IC50 (binding) | = 7 nM | BindingDB_Patents: Biological Assay. An assay for monitoring CDK4/cyclin D1-catalyzed phosphorylation of pRb at the Ser780 site was performed using TR-FRET in a 384-well format, and was used for IC50 determination and kinetic analysis. The reaction was carried out in a 30 uL volume containing 0.3 nM CDK4/cyclin D1, 150 nM biotin-pRb (773-924), 3 uM ATP, and 1.3% DMSO (or compound in DMSO) in the assay buffer (50 mM HEPES-Na, pH 7.5; 5 mM MgCl2, 1 mM DTT, 0.02% Tween-20, and 0.05% BSA). 3 uM ATP was added last to initiate the reaction. The reaction was quenched with 10 uL of 240 mM EDTA-Na (pH 8.0) after 60 min incubation at 22 C. The signal was developed by the addition of 40 uL detection solution containing 40 nM SA-APC, 143 ng/mL anti-phospho-pRb (S780) antibody, and 1 nM Eu-W1024 anti-rabbit IgG antibody in the detection buffer (50 mM HEPES-Na, pH 7.5, 60 mM EDTA-Na, pH 8.0, 0.05% BSA, and 0.1% Triton X-100). After 60 min incubation in the dark, the plate was read on Envision. | ChEMBL. | No reference |
IC50 (binding) | = 14159 nM | IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay | BINDINGDB. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.